Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis

Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments....

Full description

Saved in:
Bibliographic Details
Main Authors: Stella Bähr, Ryan W. Rue, Carly J. Smith, Jillian F. Evans, Hubert Köster, Vera P. Krymskaya, Dirk Pleimes
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Biomolecules
Subjects:
lymphangioleiomyomatosis
Nitazoxanide
lung disease
rare disease
drug repurposing
Online Access:https://www.mdpi.com/2218-273X/14/10/1236
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2218-273X/14/10/1236

Similar Items